Overview

Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy

Status:
Unknown status

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

A randomized phase II tials to study whether it's benefit of adding Nimotuzumab to chemoradiation for patients with esophageal squamous cell carcinoma after radical esophagectomy who suffer with locoregional lymph nodes recurrence.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Fudan University

Collaborators:

RenJi Hospital
Shanghai Chest Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

Nimotuzumab